Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma launches ePHEDrine Sulfate Injection, USP in the US Press Release, Product 30 December 2024 Hikma launches ePHEDrine Sulfate Injection, USP in the US
- Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US Press Release, Product 26 December 2024 Hikma receives FDA approval and launches the generic version of Victoza®, Liraglutide, in the US
- Hikma launches Indomethacin Suppositories in the US Press Release, Product 20 December 2024 Hikma launches Indomethacin Suppositories in the US
- Hikma acquires the rights to a portfolio of Takeda brands for the MENA region Press Release, Product 19 December 2024 Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
